Feed ANIP
AN

ANI Pharmaceuticals, Inc.

ANIP · NASDAQ

$74.04 +0.05% (+$0.04)
1M -0.70%
Market Cap $1.68B
P/E Ratio 15.91x
Div. Yield -
ROE 19.19%

Bulios Fair Price

$99.91

34.9% upside

Current Price

$74.04

Undervalued Fair Value Overvalued

According to Bulios Fair Price, ANIP is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Strong
7/9
Valuation
90 /100
Cheap
P/E 15.91x
EV/EBITDA 6.46x
P/S 1.72x
Growth
100 /100
Growing
Rev. growth 40.81%
Book val. growth 16.89%
EPS growth N/A
Profitability
81 /100
Strong
Gross margin 65.23%
Net margin 10.82%
Op. margin 15.35%
Quality
65 /100
Average
ROIC 9.26%
ROE 19.19%
ROA 7.08%
Debt
87 /100
Low
Debt/Equity 0.55x
Current ratio 2.91x
Int. coverage 6.20x
Stability
41 /100
Moderate
Beta 0.45x
Rev. volatility 14.00%
EPS volatility 315.31%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about ANIP
Online

About the company

ANI Pharmaceuticals, Inc. (ANI) is an American pharmaceutical company specializing in the development, manufacturing, and sale of generic and specialty pharmaceuticals. With a broad portfolio of pharmaceutical products, including generic versions of drug substances and specialty drugs for various therapeutic indications, ANI Pharmaceuticals is a recognized player in the pharmaceutical market. The company focuses on providing affordable and quality medicines for patients and healthcare facilities across the United States. ANI Pharmaceuticals also invests in research and development of new pharmaceutical products and seeks opportunities to expand its portfolio through acquisitions and licenses. ANI Pharmaceuticals, Inc. (ANI) shares could be suitable for investors seeking investment opportunities in the pharmaceutical industry and generic drugs.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Nikhil Lalwani

Employees

970

Headquarters

Baudette

Upcoming events

06 NOV

Earnings

Upcoming earnings report

42d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.